Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to its high quality affordable medicines and products.

Aspen has a market capitalisation of approximately US$10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks among the top 20 listed companies on this exchange.

As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries.

Aspen operates with an established global presence in approximately 50 emerging and developed countries spanning 6 continents and employs more than 10,000 people. The Group has 26 manufacturing facilities across 18 sites. Its emerging market footprint includes Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a developed world perspective Aspen is one of the leading pharmaceutical companies in Australia and has a growing presence in other developed countries, most notably in Western Europe.

Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are scalable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.

HomeImage

Aspen 2015 Mandela Day activities logo FINAL

 

Latest News

Stephen Saad scoops Entrepreneur of the Year Award

Johannesburg. Stephen Saad, Aspen Group Chief Executive, was announced as the winner of the Entrepreneur of the Year Award at the …

Read more »

Aspen’s comparable revenue increases by 12% to R35.4 billion

Aspen’s comparable revenue increases by 12% to R35.4 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical …

Read more »

Aspen AstraZeneca Anaesthetics Portfolio Agreement

Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca …

Read more »

More News

Featured Video

CEO Stephen Saad told CNBC Africa's Bronwyn Nielsen that the next frontier for the pharmaceutical company, which has given investors phenomenal returns, will be the United States and China

More Videos

Investor Information

Aspen 2016 Results:

Aspen 2016 Year End Results Presentation

Download PDF

Aspen 2016 Year End Results Short Form Announcement

Download PDF

Aspen 2016 Year End Results Commentary (SENS)

Download PDF

Aspen 2016 Interim Results Presentation

Download PDF

Aspen 2016 Interim Results Short Form Announcement

Download PDF

Aspen 2016 Interim Results Commentary (SENS)

Download PDF

Aspen 2015 Results:

Aspen 2015 Integrated Report

View Online Download PDF

Aspen 2015 Annual Financial Statement

View Online Download PDF

Aspen 2015 Corporate Brochure

View Online Download PDF